SAB Biotherapeutics’ (SABS) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note published on Thursday,Benzinga reports. They currently have a $12.00 price target on the stock.

A number of other equities analysts also recently issued reports on SABS. Leerink Partners initiated coverage on SAB Biotherapeutics in a research report on Wednesday, September 17th. They set an “outperform” rating and a $7.00 price target on the stock. Leerink Partnrs raised shares of SAB Biotherapeutics to a “strong-buy” rating in a research note on Wednesday, September 17th. Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 15th. Finally, Wall Street Zen upgraded shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.75.

SAB Biotherapeutics Price Performance

Shares of SABS stock opened at $3.99 on Thursday. The company has a market capitalization of $189.96 million, a P/E ratio of -1.29 and a beta of 0.58. The company’s 50-day simple moving average is $3.41 and its two-hundred day simple moving average is $2.59. SAB Biotherapeutics has a one year low of $1.00 and a one year high of $6.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.49 and a quick ratio of 10.50.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.38. As a group, equities analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SABS. ADAR1 Capital Management LLC acquired a new stake in SAB Biotherapeutics in the third quarter valued at approximately $30,000. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter valued at $32,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter valued at $40,000. HB Wealth Management LLC acquired a new stake in shares of SAB Biotherapeutics in the 3rd quarter worth $618,000. Finally, Woodline Partners LP purchased a new position in SAB Biotherapeutics during the 3rd quarter worth $5,730,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.